Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Kura Oncology, retaining the price target of $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors related to Kura Oncology’s promising developments in their farnesyl transferase inhibitor (FTI) programs. The company recently hosted an event to highlight the preclinical insights of their FTI candidates, which are being positioned as companions to targeted therapies for solid tumors.
These inhibitors, particularly tipifarnib and darlifarnib, have shown potential to enhance anti-tumor activity when combined with existing targeted therapies like tyrosine kinase inhibitors and PI3K alpha inhibitors. The need for such combination agents is underscored by the limitations of current therapies, which often face resistance issues. Kura’s approach could address these challenges, offering a novel solution for a significant patient population in the U.S., thereby transforming the treatment landscape for solid tumors.
According to TipRanks, Pantginis is an analyst with an average return of -4.0% and a 41.68% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, Krystal Biotech, and Lineage Therap.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $24.00 price target.